Scripps Polster Breast Care Center Investigational GeneBank
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 30 - Any |
| Updated: | 4/21/2016 |
| Start Date: | July 2008 |
| End Date: | June 2015 |
Breast cancer is a disease of complex origin with a strong genetic component. The incidence
of breast cancer is very high in monozygotic twins of patients, and it is thought that a
high proportion and perhaps the majority of breast cancers arise in a small number of
genetically susceptible women. Recent studies in human genetics have discovered several
intervals in the human genome containing inherited variants that are statistically
associated with the propensity to develop breast cancer. The investigators plan to use this
knowledge to design a genetic screening test to guide recommendations for breast cancer
screening with mammography. If the small group of genetically susceptible women can be
identified, more effective breast cancer screening strategies can be implemented. In
contrast, a very large proportion of women who undergo yearly mammography are at
exceptionally low risk from a genetic perspective. Using genomic guidance could eventually
reconfigure the most efficacious strategy to screen women for early detection of breast
cancer.
By developing a genetic screening panel based on genetic markers for breast cancer, the
investigators will be able to more accurately determine a woman's individual risk for
developing breast cancer.
of breast cancer is very high in monozygotic twins of patients, and it is thought that a
high proportion and perhaps the majority of breast cancers arise in a small number of
genetically susceptible women. Recent studies in human genetics have discovered several
intervals in the human genome containing inherited variants that are statistically
associated with the propensity to develop breast cancer. The investigators plan to use this
knowledge to design a genetic screening test to guide recommendations for breast cancer
screening with mammography. If the small group of genetically susceptible women can be
identified, more effective breast cancer screening strategies can be implemented. In
contrast, a very large proportion of women who undergo yearly mammography are at
exceptionally low risk from a genetic perspective. Using genomic guidance could eventually
reconfigure the most efficacious strategy to screen women for early detection of breast
cancer.
By developing a genetic screening panel based on genetic markers for breast cancer, the
investigators will be able to more accurately determine a woman's individual risk for
developing breast cancer.
Women the age of 30 or over who are undergoing screening or diagnostic breast imaging as an
out patient at the Scripps Polster Breast Care Center in La Jolla, CA, with at least 5 years
of historic breast imaging data available will be eligible to enroll. For this study,
consecutive subjects who have completed screening or diagnostic breast imaging at the
Scripps Polster Breast Care Center will be enrolled for one day. It is estimated that up to
5000 subjects will be included in the cohort.
out patient at the Scripps Polster Breast Care Center in La Jolla, CA, with at least 5 years
of historic breast imaging data available will be eligible to enroll. For this study,
consecutive subjects who have completed screening or diagnostic breast imaging at the
Scripps Polster Breast Care Center will be enrolled for one day. It is estimated that up to
5000 subjects will be included in the cohort.
Inclusion Criteria:
1. Age 30 years or older
2. Be reliable, cooperative and willing to comply with all protocol-specified procedures
3. Able to understand and grant informed consent
4. Be undergoing screening or diagnostic breast imaging
5. Have at least 5 years of breast imaging data available
Exclusion Criteria:
1. Have a significant chronic medical condition which, in the Investigator's opinion,
would interfere with the subject's participation in the study
2. Have undergone treatment with any investigational agents or devices within thirty
days preceding enrollment in the study
3. Have taken any CNS sedation or depressants in past 12 hours
We found this trial at
1
site
Click here to add this to my saved trials
